Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31642414 | 1.00 | HTR2A (0.73) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL195273 | 1.00 | HTR2A (0.73) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL29403355 | 1.00 | HTR2A (0.73) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL21309683 | 1.00 | HTR2A (0.73) | HTR2AKMT2AKDM4ELMNAMAPT | |
| Tryptophan SCHEMBL11375111 | 0.94 | KMT2A (0.78) | HTR2AKMT2AKDM4ELMNAMAPT | |
| Dl-Tryptophan SCHEMBL11375109 | 0.94 | KMT2A (0.78) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL28473836 | 0.93 | HTR2A (0.64) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL28473837 | 0.93 | HTR2A (0.64) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL18029175 | 0.89 | KMT2A (0.66) | HTR2AKMT2AKDM4ELMNAMAPT | |
| SCHEMBL456668 | 0.89 | KMT2A (0.66) | HTR2AKMT2AKDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 684 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | claimed |
| EP-3746467-B1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2025-10-08 | — | — | EP | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-20240400638-A1 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | MAGNI GUIDO (CH) | 2024-12-05 | — | — | US | claimed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | claimed |
| CN-118510796-A | Combinations of relaxin and vasopressin analogues for the treatment of renal disorders or conditions | 瑞沃2肾脏公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4392440-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | River 2 Renal Corp. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2024030977-A2 | NOVEL MELANOCORTIN ANALOGS | SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | claimed |
| EP-1646646-A1 | ANTIBIOTIC 107891, ITS FACTORS A1 AND A2, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF. | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2005014628-A1 | ANTIBIOTIC 107891, ITS FACTORS A1 AND A2, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF. | VICURON PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0421946-B1 | 3-indolepyruvic acid derivatives their method of production and therapeutic use | POLIFARMA SPA (IT) | 1996-11-20 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| EP-0203031-A2 | Biologically active lysine containing octapeptides | The Administrators of The Tulane University Educational Fund (US) | 1986-11-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | HTR2A 3159/4885KMT2A 1848/4885KDM4E 3819/4885 |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPOR, PROKR1, HBZ | HTR2A 2756/4885KMT2A 1065/4885KDM4E 1878/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | HTR2A 4753/4885KMT2A 3777/4885KDM4E 2877/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | HTR2A 2710/4885KMT2A 1567/4885KDM4E 1203/4885 |
| US-20240400638-A1 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | AVPR2, RXFP1, RXFP2 | HTR2A 672/4885KMT2A 3490/4885KDM4E 4453/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | HTR2A 799/4885KMT2A 2188/4885KDM4E 2649/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | HTR2A 2628/4885KMT2A 1568/4885KDM4E 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.